9.6/10 on Trustpilot with 47k+ reviews!

Fortekor Tablets for Dogs & Cats

Fortekor Tablets for Dogs & Cats

  • 2.5mg » Pack of 56 £32.99
  • 2.5mg » Priced per Tablet £0.59
  • 5mg » Pack of 56 £53.50
  • 5mg » Priced per Tablet £1.00
  • 20mg » Pack of 28 £57.49
  • 20mg » Priced per Tablet £2.09

Selection of 6 products from

£0.59 to £57.49

Description

Fortekor is a medication which can be used on cats or dogs but for different ailments. For dogs it is a heart failure medication and in cats is used to treat kidney failure. Dogs that use the medication may have a significantly increased lifespan and cats will find they have an increased appetite and general quality of life. Fortekor works by improving and increasing blood flow throughout the body, essential in both heart and kidney problems.

Fortekor is a small tablet which can be administered on its own or with food for ease and is available in a number of strengths depending on the size of the animal.

There can be some side effects to the medication. Cats may put on weight while using the drug but this is a positive side effect as they may have suffered weight loss with a kidney condition in the first place. Some dogs have suffered fatigue and mild dizziness but no stronger side effects have been noted in animals using the medication. There is a possibility of interaction with other drugs, so animals already on medication should be regularly monitored by a vet.

Fortekor is a prescription-only medication, which means a vet must write a prescription for it. However, it is possible to buy pet drugs online and VioVet supplies discount pet medication. The drug can also be obtained from your veterinary surgeon but this is often the most expensive way of purchasing medication. The prescription must be obtained from the vet and sent to VioVet before you can be supplied with the drug.

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Mon - Fri: 8:30am - 5:00pm
  • Sat: 9:00am - 1:00pm (Collections only)
  • Email: [email protected]

All prices include VAT where applicable.

Medication Datasheets

2.5mg » Priced per Tablet

Fortekor 2.5 for Cats and Dogs

Qualitative and quantitative composition

Active substance: Benazepril hydrochloride 2.5 mg

For a full list of excipients, see Pharmaceutical particulars section.

Pharmaceutical form

Tablets.

Beige, ovaloid, divisible, palatable tablet scored on both sides.

Clinical particulars

Target species

Dogs and cats.

Indications for use, specifying the target species

Dogs:

Treatment of congestive heart failure.

Cats:

Reduction of proteinuria associated with chronic kidney disease.

Contraindications

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal failure.

Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.

Do not use during pregnancy or lactation.

Special warnings for each target species

None.

Special precautions for use

Special precautions for use in animals

No evidence of renal toxicity of the veterinary medicinal product has been observed (in dogs or cats) during clinical trials, however, as is routine in cases of chronic kidney disease, it is recommended to monitor plasma creatinine, urea and erythrocyte counts during therapy.

The efficacy and safety of FORTEKOR has not been established in dogs and cats below 2.5 kg bodyweight.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash hands after use.

In case of accidental oral ingestion, seek medical advice immediately and show the label or the package leaflet to the physician.

Pregnant women should take special care to avoid accidental oral exposure because angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child during pregnancy in humans.

Adverse reactions (frequency and seriousness)

In double-blind clinical trials in dogs with congestive heart failure, FORTEKOR was well tolerated with an incidence of adverse reactions lower than observed in placebo-treated dogs.

A small number of dogs may exhibit transient vomiting, incoordination or signs of fatigue.

In cats and dogs with chronic kidney disease, FORTEKOR may increase plasma creatinine concentrations at the start of therapy. A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs.

FORTEKOR may increase food consumption and body weight in cats.

Emesis, anorexia, dehydration, lethargy and diarrhoea have been reported in rare occasions in cats.

Use during pregnancy, lactation or lay

Do not use during pregnancy or lactation. The safety of FORTEKOR has not been established in breeding, pregnant or lactating dogs and cats. Benazepril reduced ovary/oviduct weights in cats when administered daily at 10 mg/kg body weight for 52 weeks. Embryotoxic effects (foetal urinary tract malformation) were seen in trials with laboratory animals (rats) at maternally non-toxic doses.

Interaction with other medicinal products and other forms of interaction

In dogs with congestive heart failure, FORTEKOR has been given in combination with digoxin, diuretics, pimobendan and anti-arrhythmic veterinary medicinal products without demonstrable adverse interactions.

In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal function. The combination of FORTEKOR and other anti-hypertensive agents (e.g. calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects. Therefore, concurrent use of NSAIDs or other

medications with a hypotensive effect should be considered with care. Renal function and signs of hypotension (lethargy, weakness etc) should be monitored closely and treated as necessary. Interactions with potassium preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels when using FORTEKOR in combination with a potassium sparing diuretic because of the risk of hyperkalaemia.

Amounts to be administered and administration route

FORTEKOR should be given orally once daily, with or without food. The duration of treatment is unlimited.

FORTEKOR 2.5 mg tablets are flavoured and are taken voluntarily by most dogs and cats.

Dogs:

FORTEKOR should be administered orally at a minimum dose of 0.25 mg (range 0.25-0.5) benazepril hydrochloride/kg body weight once daily, according to the following table:

The dose may be doubled, still administered once daily, to a minimum dose of 0.5 mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the veterinary surgeon.

Cats:

FORTEKOR should be administered orally at a minimum dose of 0.5 mg (range 0.5-1.0) benazepril hydrochloride/kg body weight once daily according to the following table:

Overdose (symptoms, emergency procedures, antidotes), if necessary.

FORTEKOR reduced erythrocyte counts in normal cats when dosed at 10 mg/kg body weight once daily for 12 months and in normal dogs when dosed at 150 mg/kg body weight once daily for 12 months, but this effect was not observed at the recommended dose during clinical trials in cats or dogs.

Transient reversible hypotension may occur in cases of accidental overdose. Therapy should consist of intravenous infusion of warm isotonic saline.

Withdrawal period

Not applicable.

Pharmacological particulars

Pharmacotherapeutic group: ACE Inhibitors, plain.

ATCvet code: QC09AA07

Pharmacodynamic properties

Benazepril hydrochloride is a prodrug hydrolysed in vivo to its active metabolite, benazeprilat. Benazeprilat is a highly potent and selective inhibitor of ACE, thus preventing the conversion of inactive angiotensin I to active angiotensin II and thereby also reducing synthesis of aldosterone. Therefore, it blocks effects mediated by angiotensin II and aldosterone, including vasoconstriction of both arteries and veins, retention of sodium and water by the kidney and remodelling effects (including pathological cardiac hypertrophy and degenerative renal changes).

FORTEKOR causes long-lasting inhibition of plasma ACE activity in dogs and cats, with more than 95% inhibition at peak effect and significant activity (>80% in dogs and >90% in cats) persisting 24 hours after dosing.

FORTEKOR reduces the blood pressure and volume load on the heart in dogs with congestive heart failure.

In cats with experimental renal insufficiency, FORTEKOR normalized the elevated glomerular capillary pressure and reduced the systemic blood pressure.

Reduction in glomerular hypertension may retard the progression of kidney disease by inhibition of further damage to the kidneys. Placebo controlled clinical field studies in cats with chronic kidney disease (CKD) have demonstrated that FORTEKOR significantly reduced levels of urine protein and urine protein to creatinine ratio (UPC); this effect is probably mediated via reduced glomerular hypertension and beneficial effects on the glomerular basement membrane.

No effect of FORTEKOR on survival in cats with CKD has been shown, but FORTEKOR increased the appetite of the cats, particularly in more advanced cases.

Pharmacokinetic particulars

After oral administration of benazepril hydrochloride, peak levels of benazepril are attained rapidly (Tmax 0.5 hour in dogs and within 2 hours in cats) and decline quickly as the active substance is partially metabolised by liver enzymes to benazeprilat. The systemic bioavailability is incomplete (~13% in dogs) due to incomplete absorption (38% in dogs, <30% in cats) and first pass metabolism.

In dogs, peak benazeprilat concentrations (Cmax of 37.6 ng/ml after a dose of 0.5 mg/kg benazepril hydrochloride) are achieved with a Tmax of 1.25 hours.

In cats, peak benazeprilat concentrations (Cmax of 77.0 ng/ml after a dose of 0.5 mg/kg benazepril hydrochloride) are achieved with a Tmax of 2 hours.

Benazeprilat concentrations decline biphasically: the initial fast phase (t1/2=1.7 hours in dogs and t1/2=2.4 hours in cats) represents elimination of free drug, while the terminal phase (t1/2=19 hours in dogs and t1/2=29 hours in cats) reflects the release of benazeprilat that was bound to ACE, mainly in the tissues.

Benazepril and benazeprilat are extensively bound to plasma proteins (85-90%), and in tissues are found mainly in the liver and kidney.

There is no significant difference in the pharmacokinetics of benazeprilat when benazepril hydrochloride is administered to fed or fasted dogs. Repeated administration of FORTEKOR leads to slight bioaccumulation of benazeprilat (R=1.47 in dogs and R=1.36 in cats with 0.5 mg/kg), steady state being achieved within a few days (4 days in dogs).

Benazeprilat is excreted 54% via the biliary and 46% via the urinary route in dogs and 85% via the biliary and 15% via the urinary route in cats. The clearance of benazeprilat is not affected in dogs or cats with impaired renal function and therefore no adjustment of FORTEKOR dose is required in either species in cases of renal insufficiency.

Pharmaceutical particulars

List of excipients

Cellulose microcrystalline

Crospovidone

Povidone

Basic butylated methacrylate copolymer

Silicon dioxide anhydrous

Silica colloidal anhydrous

Sodium laurilsulphate

Dibutyl sebacate

Castor oil hydrogenated

Yeast powder

Vanillin

Incompatibilities

Not applicable.

Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 30 months.

Special precautions for storage

Do not store above 25 °C.

Store in a dry place.

Each time an unused half tablet is stored, it should be returned to the open blister space inserted back into the

cardboard box and kept in a safe place out of the reach of children.

Nature and composition of immediate packaging

PVC/PE/PVdC-aluminium blisters with 14 tablets/blister. Cardboard box with:

1 blister

2 blisters

4 blisters

Not all pack sizes may be marketed.

Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Marketing Authorisation Holder (if different from distributor)

NA

Marketing Authorisation Number

Vm 00879/4047

Date of the first authorisation or date of renewal

31 March 2003

Date of revision of the text

March 2016

Any other information

Legal category

20mg » Priced per Tablet

Fortekor Flavour 20 mg Tablets for dogs

Qualitative and quantitative composition

Each tablet contains:

Active substance: Benazepril hydrochloride 20 mg

For the full list of excipients, see Pharmaceutical particulars section.

Pharmaceutical form

Tablets.

Beige to light brown, ovaloid, divisible, tablet scored on both sides.

The tablets can be divided into halves.

Clinical particulars

Target species

Dogs.

Indications for use, specifying the target species

Dogs:

Treatment of congestive heart failure.

Contraindications

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal failure.

Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.

Do not use in pregnancy or lactation.

Special warnings for each target species

None.

Special precautions for use

Special precautions for use in animals

No evidence of renal toxicity of the veterinary medicinal product has been observed in dogs during clinical trials, however, as is routine in cases of chronic kidney disease, it is recommended to monitor plasma creatinine, urea and erythrocyte counts during therapy.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash hands after use.

In case of accidental oral ingestion, seek medical advice immediately and show the label or the package leaflet to the physician.

Pregnant women should take special care to avoid accidental oral exposure because angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child during pregnancy in humans.

Adverse reactions (frequency and seriousness)

In double-blind clinical trials in dogs with congestive heart failure, FORTEKOR Flavour was well tolerated with an incidence of adverse reactions lower than observed in placebo-treated dogs.

A small number of dogs may exhibit transient vomiting, incoordination or signs of fatigue.

In dogs with chronic kidney disease, FORTEKOR Flavour may increase plasma creatinine concentrations at the start of therapy. A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs.

Use during pregnancy, lactation or lay

The safety of FORTEKOR Flavour has not been established in breeding, pregnant or lactating dogs.

Pregnancy

Do not use during pregnancy or lactation.

Laboratory studies in rats have shown evidence of embryotoxic effects (foetal urinary tract malformation) at maternally non-toxic doses.

Interaction with other medicinal products and other forms of interaction

In dogs with congestive heart failure, FORTEKOR Flavour has been given in combination with digoxin, diuretics, pimobendan and anti-arrhythmic veterinary medicinal products without demonstrable adverse interactions.

In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal function. The combination of FORTEKOR Flavour and other anti-hypertensive agents (e.g. calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects. Therefore, concurrent use of NSAIDs or other medications with a hypotensive effect should be considered with care. Renal function and signs of hypotension (lethargy, weakness etc) should be monitored closely and treated as necessary.

Interactions with potassium preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels when using FORTEKOR Flavour in combination with a potassium sparing diuretic because of the risk of hyperkalaemia.

Amounts to be administered and administration route.

FORTEKOR Flavour should be given orally once daily, with or without food. The duration of treatment is unlimited.

FORTEKOR Flavour 20 mg tablets are flavoured and are taken voluntarily by most dogs.

FORTEKOR Flavour should be administered orally at a minimum dose of 0.25 mg (range 0.25-0.5) benazepril hydrochloride/kg body weight once daily, according to the following table:

The dose may be doubled, still administered once daily, to a minimum dose of 0.5 mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the veterinary surgeon.

Overdose (symptoms, emergency procedures, antidotes), if necessary

FORTEKOR Flavour reduced erythrocyte counts in normal dogs when dosed at 150 mg/kg body weight once daily for 12 months, but this effect was not observed at the recommended dose during clinical trials in dogs.

Transient reversible hypotension may occur in cases of accidental overdose. Therapy should consist of intravenous infusion of warm isotonic saline.

Withdrawal period

Not applicable.

Pharmacological particulars

Pharmacotherapeutic group: ACE Inhibitors, plain.

ATCvet code: QC09AA07

Pharmacodynamic properties

Benazepril hydrochloride is a prodrug hydrolysed in vivo to its active metabolite, benazeprilat. Benazeprilat is a highly potent and selective inhibitor of ACE, thus preventing the conversion of inactive angiotensin I to active angiotensin II and thereby also reducing synthesis of aldosterone. Therefore, it blocks effects mediated by angiotensin II and aldosterone, including vasoconstriction of both arteries and veins, retention of sodium and water by the kidney and remodelling effects (including pathological cardiac hypertrophy and degenerative renal changes).

FORTEKOR Flavour causes long-lasting inhibition of plasma ACE activity, with more than 95% inhibition at peak effect and significant activity (>80% in dogs) persisting 24 hours after dosing.

FORTEKOR Flavour reduces the blood pressure and volume load on the heart in dogs with congestive heart failure.

Pharmacokinetic particulars

After oral administration of benazepril hydrochloride, peak levels of benazepril are attained rapidly (Tmax 0.5 hour in dogs) and decline quickly as the active substance is partially metabolised by liver enzymes to benazeprilat. The systemic bioavailability is incomplete (~13% in dogs) due to incomplete absorption (38% in dogs) and first pass metabolism.

In dogs, peak benazeprilat concentrations (Cmax of 37.6 ng/ml after a dose of 0.5 mg/kg benazepril hydrochloride) are achieved with a Tmax of 1.25 hours.

Benazeprilat concentrations decline biphasically: the initial fast phase (t1/2=1.7 hours in dogs) represents elimination of free drug, while the terminal phase (t1/2=19 hours in dogs) reflects the release of benazeprilat that was bound to ACE, mainly in the tissues. Benazepril and benazeprilat are extensively bound to plasma proteins (85-90%), and in tissues are found mainly in the liver and kidney.

There is no significant difference in the pharmacokinetics of benazeprilat when benazepril hydrochloride is administered to fed or fasted dogs. Repeated administration of FORTEKOR Flavour leads to slight bioaccumulation of benazeprilat (R=1.47 in dogs with 0.5 mg/kg), steady state being achieved within a few days (4 days in dogs).

Benazeprilat is excreted 54% via the biliary and 46% via the urinary route in dogs. The clearance of benazeprilat is not affected in dogs with impaired renal function and therefore no adjustment of FORTEKOR Flavour dose is required in cases of renal insufficiency.

Pharmaceutical particulars

List of excipients

Cellulose microcrystalline Crospovidone Povidone Basic butylated methacrylate copolymer Silicon dioxide anhydrous Sodium laurilsulphate Dibutyl sebacate Silica colloidal anhydrous Stearic acid Yeast powder Artificial powdered beef flavor

Incompatibilities

Not applicable.

Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years

Shelf-life of tablet halves: 2 days

Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

Each time an unused half tablet is stored, it should be returned to the open blister space, inserted back into the cardboard box and kept in a safe place out of the sight and reach of children.

Nature and composition of immediate packaging

14 tablets per aluminium/aluminium blister. Cardboard box with:

1 blister (14 tablets)

2 blisters (28 tablets)

4 blisters (56 tablets)

10 blisters (140 tablets)

Not all pack sizes may be marketed.

Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Marketing Authorisation Holder (if different from distributor)

NA

Marketing Authorisation Number

Vm 00879/4046

Date of the first authorisation or date of renewal

28 April 2010

Date of revision of the text

March 2016

Any other information

Legal category

5mg » Priced per Tablet

Fortekor Flavour 5 mg tablets for cats and dogs

Qualitative and quantitative composition

Each tablet contains:

Active substance: Benazepril hydrochloride 5 mg

For the full list of excipients, see Pharmaceutical particulars section.

Pharmaceutical form

Tablets.

Beige to light brown, ovaloid, divisible, tablet scored on both sides.

The tablets can be divided into halves.

Clinical particulars

Target species

Dogs and cats.

Indications for use, specifying the target species

Dogs:

Treatment of congestive heart failure.

Cats:

Reduction of proteinuria associated with chronic kidney disease.

Contraindications

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal failure.

Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.

Do not use during pregnancy or lactation (section below).

Special warnings for each target species

None.

Special precautions for use

Special precautions for use in animals

No evidence of renal toxicity of the veterinary medicinal product has been observed (in dogs or cats) during clinical trials, however, as is routine in cases of chronic kidney disease, it is recommended to monitor plasma creatinine, urea and erythrocyte counts during therapy.

The efficacy and safety of FORTEKOR has not been established in dogs and cats below 2.5 kg body weight.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash hands after use.

In case of accidental oral ingestion, seek medical advice immediately and show the label or the package leaflet to the physician.

Pregnant women should take special care to avoid accidental oral exposure because angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child during pregnancy in humans.

Adverse reactions (frequency and seriousness)

In double-blind clinical trials in dogs with congestive heart failure, FORTEKOR Flavour was well tolerated with an incidence of adverse reactions lower than observed in placebo-treated dogs.

A small number of dogs may exhibit transient vomiting, incoordination or signs of fatigue.

In cats and dogs with chronic kidney disease, FORTEKOR Flavour may increase plasma creatinine concentrations at the start of therapy. A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs.

FORTEKOR Flavour may increase food consumption and body weight in cats.

Emesis, anorexia, dehydration, lethargy and diarrhoea have been reported in rare occasions in cats.

Use during pregnancy, lactation or lay

The safety of FORTEKOR Flavour has not been established in breeding, pregnant or lactating dogs and cats.

Pregnancy

Do not use during pregnancy or lactation.

Benazepril Reduced ovary/oviduct weights in cats when administered daily at 10 mg/kg body weight for 52 weeks.

Laboratory studies in rats have shown evidence of embryotoxic effects (foetal urinary tract malformation) at maternally non-toxic doses.

Interaction with other medicinal products and other forms of interaction

In dogs with congestive heart failure, FORTEKOR Flavour has been given in combination with digoxin, diuretics, pimobendan and anti-arrhythmic veterinary medicinal products without demonstrable adverse interactions.

In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal function. The combination of FORTEKOR Flavour and other anti-hypertensive agents (e.g. calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects. Therefore, concurrent use of NSAIDs or other medications with a hypotensive effect should be considered with care. Renal function and signs of hypotension (lethargy, weakness etc) should be monitored closely and treated as necessary.

Interactions with potassium preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels when using FORTEKOR Flavour in combination with a potassium sparing diuretic because of the risk of hyperkalaemia.

Amounts to be administered and administration route

FORTEKOR Flavour should be given orally once daily, with or without food. The duration of treatment is unlimited.

FORTEKOR Flavour 5 mg tablets are flavoured and are taken voluntarily by most dogs and cats.

Dogs:

FORTEKOR Flavour should be administered orally at a minimum dose of 0.25 mg (range 0.25-0.5) benazepril hydrochloride/kg body weight once daily, according to the following table:

The dose may be doubled, still administered once daily, to a minimum dose of 0.5 mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the veterinary surgeon.

Cats:

FORTEKOR Flavour should be administered orally at a minimum dose of 0.5 mg (range 0.5-1.0) benazepril hydrochloride/kg body weight once daily according to the following table:

Overdose (symptoms, emergency procedures, antidotes), if necessary

FORTEKOR Flavour reduced erythrocyte counts in normal cats when dosed at 10 mg/kg body weight once daily for 12 months and in normal dogs when dosed at 150 mg/kg body weight once daily for 12 months, but this effect was not observed at the recommended dose during clinical trials in cats or dogs.

Transient reversible hypotension may occur in cases of accidental overdose. Therapy should consist of intravenous infusion of warm isotonic saline.

Withdrawal period

Not applicable.

Pharmacological particulars

Pharmacotherapeutic group: ACE Inhibitors, plain.

ATC vet code: QC09AA07.

Pharmacodynamic properties

Benazepril hydrochloride is a prodrug hydrolysed in vivo to its active metabolite, benazeprilat. Benazeprilat is a highly potent and selective inhibitor of ACE, thus preventing the conversion of inactive angiotensin I to active angiotensin II and thereby also reducing synthesis of aldosterone. Therefore, it blocks effects mediated by angiotensin II and aldosterone, including vasoconstriction of both arteries and veins, retention of sodium and water by the kidney and remodelling effects (including pathological cardiac hypertrophy and degenerative renal changes).

FORTEKOR Flavour causes long-lasting inhibition of plasma ACE activity in dogs and cats, with more than 95% inhibition at peak effect and significant activity (>80% in dogs and >90% in cats) persisting 24 hours after dosing.

FORTEKOR Flavour reduces the blood pressure and volume load on the heart in dogs with congestive heart failure.

In cats with experimental renal insufficiency, FORTEKOR Flavour normalized the elevated glomerular capillary pressure and reduced the systemic blood pressure.

Reduction in glomerular hypertension may retard the progression of kidney disease by inhibition of further damage to the kidneys. Placebo controlled clinical field studies in cats with chronic kidney disease (CKD) have demonstrated that FORTEKOR Flavour significantly reduced levels of urine protein and urine protein to creatinine ratio (UPC); this effect is probably mediated via reduced glomerular hypertension and beneficial effects on the glomerular basement membrane.

No effect of FORTEKOR Flavour on survival in cats with CKD has been shown, but FORTEKOR Flavour increased the appetite of the cats, particularly in more advanced cases.

Pharmacokinetic particulars

After oral administration of benazepril hydrochloride, peak levels of benazepril are attained rapidly (Tmax 0.5 hour in dogs and within 2 hours in cats) and decline quickly as the active substance is partially metabolised by liver enzymes to benazeprilat. The systemic bioavailability is incomplete (~13% in dogs) due to incomplete absorption (38% in dogs, <30% in cats) and first pass metabolism.

In dogs, peak benazeprilat concentrations (Cmax of 37.6 ng/ml after a dose of 0.5 mg/kg benazepril hydrochloride) are achieved with a Tmax of 1.25 hours.

In cats, peak benazeprilat concentrations (Cmax of 77.0 ng/ml after a dose of 0.5 mg/kg benazepril hydrochloride) are achieved with a Tmax of 2 hours.

Benazeprilat concentrations decline biphasically: the initial fast phase (t1/2=1.7 hours in dogs and t1/2=2.4 hours in cats) represents elimination of free drug, while the terminal phase (t1/2=19 hours in dogs and t1/2=29 hours in cats) reflects the release of benazeprilat that was bound to ACE, mainly in the tissues. Benazepril and benazeprilat are extensively bound to plasma proteins (85-90%), and in tissues are found mainly in the liver and kidney.

There is no significant difference in the pharmacokinetics of benazeprilat when benazepril hydrochloride is administered to fed or fasted dogs. Repeated administration of FORTEKOR Flavour leads to slight bioaccumulation of benazeprilat (R=1.47 in dogs and R=1.36 in cats with 0.5 mg/kg), steady state being achieved within a few days (4 days in dogs).

Benazeprilat is excreted 54% via the biliary and 46% via the urinary route in dogs and 85% via the biliary and 15% via the urinary route in cats. The clearance of benazeprilat is not affected in dogs or cats with impaired renal function and therefore no adjustment of FORTEKOR Flavour dose is required in either species in cases of renal insufficiency

Pharmaceutical particulars

List of excipients

Cellulose microcrystalline Crospovidone Povidone Basic butylated methacrylate copolymer Silicon dioxide anhydrous Sodium laurilsulphate Dibutyl sebacate Silica colloidal anhydrous Stearic acid Yeast powder Artificial powdered beef flavour

Incompatibilities

Not applicable.

Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years

Shelf-life of tablet halves: 2 days

Special precautions for storage

Do not store above 25 °C.

Each time an unused half tablet is stored, it should be returned to the open blister space, inserted back into the cardboard box and kept in a safe place out of the sight and reach of children.

Nature and composition of immediate packaging

14 tablets per aluminium/aluminium blister. Cardboard box with:

1 blister (14 tablets)

2 blisters (28 tablets)

4 blisters (56 tablets)

10 blisters (140 tablets)

Not all pack sizes may be marketed.

Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Marketing Authorisation Holder (if different from distributor)

NA

Marketing Authorisation Number

Vm 00879/4045

Date of the first authorisation or date of renewal

28 April 2010

Date of revision of the text

March 2016

Any other information

Legal category

Delivery Information

How quickly do you deliver?

Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.

What do you charge for delivery?

For UK delivery, we charge the following:

Order Total Weight Delivery
£0-£28.99 Under 2kg £2.99
2kg+ £4.99
£29-£38.99 Under 2kg Free
2kg+ £4.99
£39+ Under 2kg Free
2kg+ Free

Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products, such as Insulin, are also not always subject to the standard and/or free delivery options.

For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.

We can deliver most items to all around the world, but prices do vary. The majority of light weight orders (less than 1.5kg) can be delivered for a flat rate of £10. For an accurate estimate of the delivery charge, please put the items you require in your basket and use the "Estimate Delivery" system on the shopping basket page (you only need to enter your country and postal/zip code) for a quick quote. For deliveries to the USA you may need to go to the checkout page and enter your full address to get a quote (as some services need your state in order to quote too). For more information on international deliveries, please see our delivery information page.

Delivery of aerosols

Due to restrictions aerosols can't be sent by Royal Mail. We appreciate your understanding.

Delivery of temperature controlled items

Some products, such as insulin and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a £1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the £1.99 once per order, regardless of how many temperature controlled items you purchase in that order.

How do I cancel or return an order?

Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.

To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.

*For full details on returns, see our terms and conditions page.

Reviews (72)

Q & A

Below are some recent questions we've received regarding Fortekor Tablets for Dogs & Cats, including answers from our team.

8 October 2015 at 7:52pm

Fortekor

Goldie

We starting using this yesterday, with diuretics for congestive heart failure and liver function - drinking LOADS!
Now his heartbeat is visibley stronger but he's shattered and won't eat, trying to start a new prescription diet doesn't help. He has lost so much weight worried about the lack of calories he is getting.
Is this normal in the first few days?

  • Non-Executive Director

This is not ideal. There is sometimes a problem if you start the Fortekor and diuretic at the same time. It can be best to stagger them and wait a few days between starting these two types of medication. Dehysdration is a risk, despite the great thrist, which will not help. I would consider adjusting the medication but you will have to talk to your own vet about this as I am not familiar enough with your dog to be able to advise better than that. Do contact your vet straight away.

8 September 2015 at 9:24am

Enalapril or Fortekor

David

  • VioVet customer since 2014
  • From: , Singapore

Actually i know both are ACE inhibitor. but what is the difference between them ? Why should i pick one over another? Can anyone elaborate? thank you so much!

  • Non-Executive Director

They are indeed both ACE inhibitors which means that they work through the same sort of mechanism in the body. They are both prescription-only so your vet will choose which one to prescribe. The drugs are marginally different (Fortekor contains benazepril) but the consequence of any differences is unlikely to be significant for most dogs. Both are pro-drugs which are converted in the body to the active forms. With benazepril this active form undergoes hepatic excretion, a possible advantage in animals with renal failure, whereas with enalapril, the active form is more extensively cleared from the body by the kidneys. A potential build up in the body in dogs with poor kidney function is perhaps more likely.

14 August 2015 at 10:51am

Fortekor plus Vivitonin

Robert

  • VioVet customer since 2015
  • From: Argyll and Bute, United Kingdom

My 13 year old 20kg dog was prescribed Vivitonin 100mgx2 daily after a CVD attack. Later she was also put on Fortekor 5mg daily for a grade 4 murmur.

Are the two drugs compatible or are there any interactions or cautions?

With thanks

  • Non-Executive Director

These two drugs are often used together and they should be fine. Other drugs may be added too if the heart problems gets worse and Vivitonin should be OK with all the usual choices.

21 May 2015 at 3:28pm

Drug interactions

Lynsey

Hi my dog has been put on Fortekor 20mg Vetmedin 1.25mg and frusemide 20mg. Is it still safe for her to take Yumove tablets daily as this helps with her mobilty?
Thanks

  • Non-Executive Director

All these tablets, including Yumove, are often used together in older dogs and as far as we can tell, they are perfectly safe and effective given that way. I am sure you can include Yumove for her mobility.